Objective To explore the clinical and molecular pathological features of primary glioblastoma(PGBM),along with the factors influencing its prognosis.Methods The clinical data and molecular pathology results of 49 PGBM patients who underwent surgical resection in the Affiliated Provincial Hospital of Anhui Medical University from January 2021 to July 2022 were analyzed retrospectively.Variables including gender,age,extent of tumor resection,postoperative treatment modalities,as well as genetic expressions such as MGMT promoter methylation,TP53 mutation,CDK4/6 amplification,and NF1 mutation were scrutinized.Statistical analyses were employed to correlate these clinical features and genetic mutations with patients'progression-free survival and overall survival.Results Male patients(65.30％)outnumbered female patients(34.70％).Gross total resection accounted for 81.60％,while subtotal resection or partial resection constituted 18.4％.Postoperatively,standard adjuvant chemoradiotherapy was predominantly administered(63.30％).Molecular pathology assessments revealed MGMT promoter methylation positivity in 55.10％,TP53 mutation in 38.78％,CDK4/6 amplification in 48.98％,and NF1 mutation in 28.57％of cases.Correlation analysis indicated that extent of resection,postoperative adjuvant chemoradiotherapy,MGMT promoter methylation,TP53 mutation,and CDK4/6 amplification were independent prognostic factors(P＜0.05),while NF1 mutation showed no significant correlation with prognosis(P＞0.05).Conclusions The clinical characteristics and some gene mutations of PGBM patients are closely related to prognosis.Age,extent of tumor resection,postoperative treatment modalities,as well as MGMT promoter methylation,TP53 mutation,and CDK4/6 amplification,emerge as crucial indicators for predicting prognosis in PGBM patients,while further research is warranted to elucidate the impact of NF1 mutation on prognosis.These insights contribute to refining individualized treatment strategies and prognosis assessment for PGBM patients.
维普
万方数据
